Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

Literature DB >> 26709483

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

Carrie Lee¹, Dimitry Usenko, Garrett M Frampton, Caitlin McMahon, Siraj M Ali, Jared Weiss.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26709483 DOI： 10.1097/JTO.0000000000000645

Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors: Thanyanan Reungwetwattana; Sai-Hong Ignatius Ou
Journal: Transl Lung Cancer Res Date: 2015-12

2. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping.

Authors: Joon Young Hur; Bo Mi Ku; Joon Ho Shim; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155

Review 3. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors: Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal: Ann Transl Med Date: 2017-01

Review 4. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors: Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal: J Thorac Oncol Date: 2016-10-26 Impact factor: 15.609

5. A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.

Authors: Rui Jiang; Dongguang Wei; Yuan Tan; Qianqian Duan
Journal: Invest New Drugs Date: 2022-05-12 Impact factor: 3.651

6. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Authors: J K Sabari; G C Leonardi; C A Shu; R Umeton; J Montecalvo; A Ni; R Chen; J Dienstag; C Mrad; I Bergagnini; W V Lai; M Offin; K C Arbour; A J Plodkowski; D F Halpenny; P K Paik; B T Li; G J Riely; M G Kris; C M Rudin; L M Sholl; M Nishino; M D Hellmann; N Rekhtman; M M Awad; A Drilon
Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

1. MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

2. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping.

Review 3. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Review 4. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

5. A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.

6. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Review 7. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.

8. Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database.

9. Expression of HIF-1α and P-gp in non-small cell lung cancer and the relationship with HPV infection.

Review 10. Pulmonary spindle cell carcinoma with unusual morphology: A rare case report and review of the literature.